Narsoplimab clinical trials
Also written OMS721.
How each study uses narsoplimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the narsoplimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 23 Dec 2025 · YARTEMLEA · BLA 761152 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2020 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Omeros Corporation (5) · QuantumLeap Healthcare Collaborative (1)
Often tested with
Tested in the same studies.
Remdesivir (1) · Imatinib (1) · Dexamethasone (1) · Cenicriviroc (1) · Icatibant (1) · Apremilast (1) · Dornase alfa (1) · Celecoxib (1)
Studies
Open first, then newest update. How each study uses narsoplimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMARecruitingPhase 2Omeros CorporationNCT05855083Written as Biological: narsoplimab
- Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721TerminatedPhase 2Omeros CorporationNCT02682407Written as OMS721 (narsoplimab)
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsActive, not recruitingPhase 2QuantumLeap Healthcare CollaborativeNCT04488081Written as narsoplimab
- Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic SyndromeTerminatedPhase 3Omeros CorporationNCT03205995Written as OMS721 (narsoplimab)
- Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) NephropathyTerminatedPhase 3Omeros CorporationNCT03608033Written as OMS721
- Safety and Efficacy Study of OMS721 in Patients With Thrombotic MicroangiopathiesCompletedPhase 2Omeros CorporationNCT02222545Written as OMS721
Codes
What other systems call narsoplimab · ClinicalTrials.gg INT001703
- MeSH (NLM) C000718989narsoplimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) FT24ZQQ5RPNARSOPLIMABConfirmed FDA, NLM
- NCI Thesaurus C119952NarsoplimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718989 | narsoplimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | FT24ZQQ5RP | NARSOPLIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C119952 | Narsoplimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.